首页> 外国专利> Crystal form I of 2-methyl-4- (4-methyl-1-piperazinyl) -10H-thieno 2,3-b 1,5 benzodiazepine, process for the preparation of this crystal form I, and pharmaceutical composition

Crystal form I of 2-methyl-4- (4-methyl-1-piperazinyl) -10H-thieno 2,3-b 1,5 benzodiazepine, process for the preparation of this crystal form I, and pharmaceutical composition

机译:2-甲基-4-(4-甲基-1-哌嗪基)-10H-噻吩并[2,3-b] [1,5]苯并二氮杂I的晶型I,该晶型I的制备方法和药物组合物

摘要

Crystalline form I of 2-methyl-4-(4-rnethyl-1-piperazinyl)-10H-tnieno[2,3-b][1,5]benzodiazepine characterized by x-ray powder diffraction peaks at approximately 9.94, 8.53, 8.19, 6.86, 6.35, 5.47, 4.83, 4.71, 4.53, 4.22, 4.08, 3.82, 3.75, 3.69, 3.50, 3.34, 3.11, 2.94, 2.82, 2.76, 2.59, 2.34, 2.03, 1.92 d (interplanar spacing) values; infrared absorbance bands at approximately 1456, 1365, 905, 757, 662 & 604 cm-1 and having stable colour at ambient conditions of storage; and the process of its preparation comprising at least two repetitive steps of crystallization from one or more organic solvent by dissolving 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thienol[2,3-b][1,5]benzodiazepine in said solvent and allowing crystallization to occur; wherein in at least one step the solution is purified by treating with a solid adsorbent material and filtering; and wherein in the last step the crystalline material is subjected to drying.
机译:2-甲基-4-(4-甲基-1-哌嗪基)-10H-替尼诺[2,3-b] [1,5]苯并二氮杂I的结晶形式I,其特征在于X射线粉末衍射峰位于大约9.94、8.53, 8.19,6.86,6.35,5.47,4.83,4.71,4.53,4.22,4.08,3.82,3.75,3.69,3.50,3.34,3.11,2.94,2.82,2.76,2.59,2.34,2.03,1.92 d(面间距)值;在大约1456、1365、905、757、662和604 cm-1处的红外吸收带,并在环境存储条件下具有稳定的颜色;及其制备方法,其包括通过溶解2-甲基-4-(4-甲基-1-哌嗪基)-10H-噻吩[2,3-b] [1]从一种或多种有机溶剂中结晶的至少两个重复步骤。 ,5]在所述溶剂中的苯并二氮杂并允许结晶发生;其中在至少一步中,通过用固体吸附剂材料处理并过滤来纯化溶液;其中在最后一步中将结晶材料进行干燥。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号